Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Eiger BioPharmaceuticals, Inc.

http://www.eigerbio.com/

Latest From Eiger BioPharmaceuticals, Inc.

Eiger's Lonafarnib Loses EU Fast-Track Review Status

Eiger attributes the change in status of the EU marketing authorization application for lonafarnib to the need for an inspection and the ongoing coronavirus pandemic.

Europe Drug Review

Stacked User Fee Calendar Puts Another Record-Setting Year For US FDA Novel Approvals Within Reach

With goal dates for almost 40 novel drugs and biologics coming up in the second half of 2020 after a record number of first half approvals, even the pandemic looks unlikely to prevent another solid year for innovative drugs at US FDA.

Drug Review Review Pathway

EU Accelerated Assessment Tracker

At least another four investigational therapies will join the few that are already being fast-tracked at the European Medicines Agency.

Europe Drug Review

EU Accelerated Assessment Tracker

Alnylam and Eiger join the select group of companies whose products have been granted fast-track status at the European Medicines Agency

Review Pathway Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Celladon Corporation
UsernamePublicRestriction

Register